TWI531650B - 用於預防及治療非酒精性脂肪肝疾病的腺病毒ａｄ３６ ｅ４ｏｒｆ１蛋白 - Google Patents
用於預防及治療非酒精性脂肪肝疾病的腺病毒ａｄ３６ ｅ４ｏｒｆ１蛋白 Download PDFInfo
- Publication number
- TWI531650B TWI531650B TW100124173A TW100124173A TWI531650B TW I531650 B TWI531650 B TW I531650B TW 100124173 A TW100124173 A TW 100124173A TW 100124173 A TW100124173 A TW 100124173A TW I531650 B TWI531650 B TW I531650B
- Authority
- TW
- Taiwan
- Prior art keywords
- protein
- adenovirus
- nucleic acid
- liver
- seq
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 92
- 102000004169 proteins and genes Human genes 0.000 title claims description 83
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims description 35
- 238000011282 treatment Methods 0.000 title claims description 12
- 230000002265 prevention Effects 0.000 title claims description 6
- 241000701161 unidentified adenovirus Species 0.000 title description 8
- 210000004185 liver Anatomy 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 150000002632 lipids Chemical class 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 21
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 20
- 206010022489 Insulin Resistance Diseases 0.000 claims description 16
- 238000001890 transfection Methods 0.000 claims description 15
- 238000001415 gene therapy Methods 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 12
- 230000003647 oxidation Effects 0.000 claims description 12
- 238000007254 oxidation reaction Methods 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 208000019423 liver disease Diseases 0.000 claims description 11
- 230000005976 liver dysfunction Effects 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 6
- 108091061960 Naked DNA Proteins 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 230000005684 electric field Effects 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 6
- 238000002744 homologous recombination Methods 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 210000001938 protoplast Anatomy 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 75
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 65
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 65
- 239000008103 glucose Substances 0.000 description 62
- 208000015181 infectious disease Diseases 0.000 description 42
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 42
- 235000005911 diet Nutrition 0.000 description 41
- 230000037213 diet Effects 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- 102000011690 Adiponectin Human genes 0.000 description 30
- 108010076365 Adiponectin Proteins 0.000 description 30
- 210000000577 adipose tissue Anatomy 0.000 description 30
- 230000002641 glycemic effect Effects 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 27
- 235000019197 fats Nutrition 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 21
- 229940125396 insulin Drugs 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 19
- 230000002440 hepatic effect Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 13
- 235000021590 normal diet Nutrition 0.000 description 12
- 230000004190 glucose uptake Effects 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 229920002527 Glycogen Polymers 0.000 description 9
- 108010016731 PPAR gamma Proteins 0.000 description 9
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 229940096919 glycogen Drugs 0.000 description 9
- 230000006372 lipid accumulation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101150116689 Slc2a2 gene Proteins 0.000 description 8
- 229940123464 Thiazolidinedione Drugs 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 150000001467 thiazolidinediones Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 210000000229 preadipocyte Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 5
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000007446 glucose tolerance test Methods 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 230000004132 lipogenesis Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000007863 steatosis Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241000205594 Human adenovirus 36 Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 235000013367 dietary fats Nutrition 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 101150110386 SLC2A4 gene Proteins 0.000 description 3
- 101100038645 Streptomyces griseus rppA gene Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 101150102415 Apob gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 2
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 2
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 2
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 2
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 101150058068 SLC2A1 gene Proteins 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000004311 liver X receptors Human genes 0.000 description 2
- 108090000865 liver X receptors Proteins 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 102000003808 Adiponectin Receptors Human genes 0.000 description 1
- 108090000179 Adiponectin Receptors Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 101710108331 Bifunctional oligoribonuclease and PAP phosphatase NrnA Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710189078 Helicase Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 101710105047 Lipoprotein B Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008727 cellular glucose uptake Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 102000028561 sterol response element binding proteins Human genes 0.000 description 1
- 108091009326 sterol response element binding proteins Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36244310P | 2010-07-08 | 2010-07-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201217529A TW201217529A (en) | 2012-05-01 |
| TWI531650B true TWI531650B (zh) | 2016-05-01 |
Family
ID=44629893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100124173A TWI531650B (zh) | 2010-07-08 | 2011-07-08 | 用於預防及治療非酒精性脂肪肝疾病的腺病毒ａｄ３６ ｅ４ｏｒｆ１蛋白 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8951980B2 (enExample) |
| EP (1) | EP2590665B1 (enExample) |
| JP (1) | JP5965397B2 (enExample) |
| KR (1) | KR101831638B1 (enExample) |
| CN (1) | CN103052397B (enExample) |
| AU (1) | AU2011274537B9 (enExample) |
| CA (1) | CA2803787C (enExample) |
| ES (1) | ES2550962T3 (enExample) |
| NZ (1) | NZ606236A (enExample) |
| TW (1) | TWI531650B (enExample) |
| WO (1) | WO2012006512A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014062794A1 (en) | 2012-10-17 | 2014-04-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for improving glucose uptake |
| US9354963B2 (en) * | 2014-02-26 | 2016-05-31 | Microsoft Technology Licensing, Llc | Service metric analysis from structured logging schema of usage data |
| US10047107B2 (en) | 2014-04-23 | 2018-08-14 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Small molecule analogs of E4orf1 |
| GB201910299D0 (en) * | 2019-07-18 | 2019-09-04 | Aouadi Myriam | Medical uses, methods and uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004004775T2 (de) * | 2004-08-12 | 2007-11-22 | Roche Diagnostics Gmbh | Verfahren zur Diagnose von Leberfibrose. |
| US20060045919A1 (en) | 2004-08-27 | 2006-03-02 | Samueli Institute | Homeopathic compositions and methods for the treatment of cancer |
| JP2008105945A (ja) * | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
| ES2472325T3 (es) * | 2005-11-30 | 2014-06-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Gen y proteína del adenovirus 36 E4 orf 1 y sus usos |
| WO2007120362A2 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| JP2008273938A (ja) * | 2007-03-30 | 2008-11-13 | Shiseido Co Ltd | アディポネクチン産生促進剤 |
-
2011
- 2011-07-08 EP EP11741354.2A patent/EP2590665B1/en not_active Not-in-force
- 2011-07-08 TW TW100124173A patent/TWI531650B/zh not_active IP Right Cessation
- 2011-07-08 KR KR1020137001869A patent/KR101831638B1/ko not_active Expired - Fee Related
- 2011-07-08 CN CN201180033866.7A patent/CN103052397B/zh not_active Expired - Fee Related
- 2011-07-08 JP JP2013518858A patent/JP5965397B2/ja not_active Expired - Fee Related
- 2011-07-08 ES ES11741354.2T patent/ES2550962T3/es active Active
- 2011-07-08 NZ NZ606236A patent/NZ606236A/en not_active IP Right Cessation
- 2011-07-08 WO PCT/US2011/043338 patent/WO2012006512A1/en not_active Ceased
- 2011-07-08 CA CA2803787A patent/CA2803787C/en not_active Expired - Fee Related
- 2011-07-08 US US13/178,986 patent/US8951980B2/en not_active Expired - Fee Related
- 2011-07-08 AU AU2011274537A patent/AU2011274537B9/en not_active Ceased
-
2015
- 2015-01-06 US US14/590,262 patent/US20170340699A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130100262A (ko) | 2013-09-10 |
| JP5965397B2 (ja) | 2016-08-03 |
| JP2013531681A (ja) | 2013-08-08 |
| AU2011274537A1 (en) | 2013-02-14 |
| KR101831638B1 (ko) | 2018-02-23 |
| AU2011274537B9 (en) | 2017-02-23 |
| NZ606236A (en) | 2014-09-26 |
| CN103052397B (zh) | 2017-09-19 |
| WO2012006512A1 (en) | 2012-01-12 |
| EP2590665A1 (en) | 2013-05-15 |
| CA2803787A1 (en) | 2012-01-12 |
| US20170340699A1 (en) | 2017-11-30 |
| TW201217529A (en) | 2012-05-01 |
| CA2803787C (en) | 2018-12-04 |
| AU2011274537B2 (en) | 2016-12-15 |
| HK1185261A1 (en) | 2014-02-14 |
| US20120027845A1 (en) | 2012-02-02 |
| ES2550962T3 (es) | 2015-11-13 |
| EP2590665B1 (en) | 2015-09-16 |
| US8951980B2 (en) | 2015-02-10 |
| CN103052397A (zh) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnapuram et al. | Template to improve glycemic control without reducing adiposity or dietary fat | |
| Cariou | The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: implications for treatment | |
| Kim et al. | The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes | |
| Yan et al. | Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart | |
| Choe et al. | Macrophage HIF-2α ameliorates adipose tissue inflammation and insulin resistance in obesity | |
| De Minicis et al. | From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights | |
| Dadson et al. | Adiponectin action: a combination of endocrine and autocrine/paracrine effects | |
| Harrison et al. | Advances in the understanding and treatment of nonalcoholic fatty liver disease | |
| Steinberg et al. | The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity | |
| Kumar et al. | Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis | |
| Piao et al. | A novel plasminogen activator inhibitor‐1 inhibitor, TM5441, protects against high‐fat diet‐induced obesity and adipocyte injury in mice | |
| Guo et al. | A novel NEDD4L-TXNIP-CHOP axis in the pathogenesis of nonalcoholic steatohepatitis | |
| Zilu et al. | Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress | |
| US20170340699A1 (en) | Adenovirus AD36 E4ORF1 Protein For Prevention and Treatment of Non-Alcoholic Fatty Liver Disease | |
| Li et al. | Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway | |
| WO2018028433A1 (zh) | Creg蛋白用于预防或治疗体重超重、肥胖及其相关疾病的医药用途 | |
| US10729634B2 (en) | Sex hormone-binding globulin for use as a medicament | |
| Boutari et al. | Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons | |
| HK1185261B (en) | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease | |
| US20200377565A1 (en) | Brown Fat-Selective Adipokines | |
| US8546347B2 (en) | Composition for treatment and improvement of diabetes comprising caveolin as active ingredient and a method for treatment of diabetes using it | |
| US20250281572A1 (en) | Compositions and methods for treating and preventing metabolic disorders | |
| Cefalu et al. | Template to improve glycemic control without | |
| US20120269796A1 (en) | Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes | |
| CN119792581A (zh) | TrkB基因在制备肝纤维化治疗产品中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |